Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.55 USD

76.55
859,950

+1.47 (1.96%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $76.58 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 252)

Industry: Medical - Products

Better trading starts here.

Zacks News

Integra Announces Preliminary Q4 Results, Share Buyback Plan

Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.

Boston Scientific Stock Dips on Dull Preliminary Q4 Results

Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.

Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now

Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.

LabCorp Hits New 52-Week High: What's Driving the Stock?

LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.

CVS Health's Selling Seasons Strong, Omnicare Arm Upsets

CVS Health's (CVS) 2020 PBM selling season remains strong with gross new business and net new business wins.

Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan

Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.

Thermo Fisher Hits New 52-Week High: What's Driving the Stock?

Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.

Medtronic's Neurostimulator DBS System Receives CE Mark

Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.

Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift

Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.

Globus Medical Stock Up on Solid '19 Preliminary Results

Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.

Medtronic (MDT) Buys Stimgenics, To Present New Trial Results

Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.

Varian (VAR) Hits a 52-Week High: What's Driving the Stock?

Varian (VAR) gains from several positive developments.

Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod

Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q3.

Amedisys Gains on Favorable Demography, New Hospice Buyouts

Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.

Exact Sciences Rides on Cologuard, Eyes Merger Synergies

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Here's Why You Should Add STERIS (STE) to Portfolio Now

Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.

Neogen Expands in South America With Productos Acquisition

Neogen (NEOG) expands operations in South America by acquiring its food safety diagnostics distributor partner that operates in Argentina and Uruguay.

Urmimala Biswas headshot

LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds

LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).

Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now

Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

Investors continue to be optimistic about Align Technology (ALGN) on its stellar segmental performance in Q3.

Here's Why You Should Hold on to Phibro (PAHC) Stock Now

Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.

Hill-Rom Hits New 52-Week High: What's Driving the Stock?

Hill-Rom (HRC) is optimistic about maintaining its growth momentum on several recent developments.

Amedisys Completes Asana Hospice Acquisition, Expands Network

Amedisys (AMED) closes Asana takeover to strengthen its hospice care network.